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Abstract
Patients with myotonic muscular dystrophy type 1 (DM1) tend to exhibit earlier respiratory insufﬁciency than patients with other
neuromuscular diseases at similar or higher forced vital capacity (FVC). This study aimed to analyze several pulmonary function
parameters to determine which factor contributes the most to early hypercapnia in patients with DM1.
We analyzed ventilation status monitoring, pulmonary function tests (including FVC, maximal voluntary ventilation [MVV], and
maximal inspiratory and expiratory pressure), and polysomnography in subjects with DM1 who were admitted to a single university
hospital. The correlation of each parameter with hypercapnia was determined. Subgroup analysis was also performed by dividing the
subjects into 2 subgroups according to usage of mechanical ventilation.
Final analysis included 50 patients with a mean age of 42.9 years (standard deviation=11.1), 46.0% of whom were male. The
hypercapnia was negatively correlated with MVV, FVC, forced expiratory volume in 1 second (FEV1), and their ratios to predicted
values in subjects with myotonic muscular dystrophy type 1. At the same partial pressure of carbon dioxide, the ratio to the
predicted value was lowest for MVV, then FEV1, followed by FVC. Moreover, the P values for differences in MVV and its ratio to the
predicted value between ventilator users and nonusers were the lowest.
When screening ventilation failure in patients with DM1, MVV should be considered alongside other routinely measured
parameters.
Abbreviations: CTG = cytosine–thymine–guanine, DM1 =myotonic muscular dystrophy type 1, DMPK = dystrophia myotonica
protein kinase, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, MEP =maximal expiratory pressure, MIP =
maximal inspiratory pressure, MMD=myotonic muscular dystrophy, MVV=maximal voluntary ventilation, pCO2= partial pressure of
carbon dioxide.
Keywords: forced vital capacity, hypercapnia, maximal voluntary ventilation, myotonic muscular dystrophy, neuromuscular
disease, ventilation failure1. Introduction
Myotonic muscular dystrophy type 1 (DM1), caused by an
abnormal cytosine–thymine–guanine (CTG) repeat expansion in
the region of the dystrophia myotonica protein kinase (DMPK)
gene,[1–4] is one of the most common neuromuscular diseases. The
expanded repeat is transcribed in RNA and forms discrete
inclusions in the nucleus, leading to muscle ﬁber hyperexcitability
and impaired transmembrane conductance of either chloride orEditor: Giuseppe Insalaco.
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1sodium ions.[5,6] Patients are characterized by “myotonia,” a term
referring to delayed relaxation of muscle ﬁbers. Thus, unlike
patients with other types of neuromuscular diseases who exhibit
only progressive loss of muscle ﬁbers, patients with DM1 exhibit
difﬁculty in contraction–relaxation coordination before exhibiting
actual muscle weakness.[7] Symptomatic patients demonstrate
difﬁculty in relaxing their grip during repeated grasping and
releasing movements. Cardiac muscles predominantly exhibitlication and afﬁrm that this report is consistent with those guidelines.
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cardiomyopathies are usually secondary to arrhythmia and
ventilatory failure.[4,7–9] Most likely, the diaphragm and intercos-
tal muscles, which enable rhythmic breathing by contraction and
passive relaxation, can also be affected by myotonia.[9,10]
Most neuromuscular disorders, including DM1, with progres-
sive respiratory muscle weakness result in an increase in partial
pressure of carbon dioxide (pCO2),
[11,12] and hypercapnia
demonstrates a correlation with pulmonary function.[13] For
example, decline in total lung capacity is strongly correlated with
hypoxemia and hypercapnia in patients with myotonic muscular
dystrophy (MMD).[14] However, in our experience, patients with
DM1 tend to exhibit earlier respiratory insufﬁciency than
patients with other neuromuscular diseases at similar or higher
pulmonary function, including forced vital capacity (FVC).[15]
Aside from respiratory muscle weakness, there are also other
mechanisms that explain ventilation failure in DM1, including
alterations in respiratory mechanics and abnormal central
respiratory control.[14,16]
Meanwhile, maximal voluntary ventilation (MVV) is one of
the pulmonary function parameters used to determine respira-
tory muscle endurance. The standard method of measuring
MVV is to let the patient breathe as fast and hard as possible for
12 seconds, then multiply the total ﬂow volume by 5 to yield the
total volume of ventilation per minute (expressed as L/min).[17]
Unlike most of other parameters that measure the pulmonary
function for brief seconds,MVV enablesmeasurement of longer
ﬂows. Reductions in MVV were known to be associated with
expiratory phase slowing in the previous report.[17] Theoreti-
cally, it reﬂects both inspiratory and expiratory phase
dysfunction and airway resistance, forMVVmeasuresmaximal
volume of air inspired and expired for >12 seconds.[18]
Myotonia of the diaphragm—typical in patients with DM1—
might not be easily detected in shorter phase examinations such
as FVC or forced expiratory volume in 1 second (FEV1).
However, it can be revealed in examinations conducted for
longer phases, such as MVV.
We hypothesized thatMVV decreases before other parameters,
such as FVC, in patients with DM1, and thatMVVwould decline
more abruptly in correlation with the progression of respiratory
dysfunction in these patients. Accordingly, this study aimed to
analyze several pulmonary function parameters to determine
which factor contributes themost to early hypercapnia in patients
with DM1.
2. Materials and methods
2.1. Participants
This is an observation study enrolling subjects with DM1 who
were admitted to a single university hospital for routine annual
check-up between March 2015 and March 2018. Individuals
who were not able to undergo the pulmonary function tests (e.g.,
those with intellectual disabilities), and those with acute
pulmonary disease conditions (e.g., pneumonia, pneumothorax,
and so on) which may have affected the test results, were
excluded. This study was approved by the institutional review
board of the authors’ hospital (3-2016-0182).2.2. Study design
We retrospectively collected the data of pulmonary function
testing, including FVC, FEV1, and MVV. Data of maximal2inspiratory pressure (MIP) and maximal expiratory pressure
(MEP) were also collected.
FVC which is the complete expiratory volume from a position
of full inspiration[19] and FEV1 which reﬂects elastic recoil and
airway resistance[20] (both measured simultaneously) were tested
using spirometry (Pony FX, COSMED, Rome, Italy) at least 3
times, and the best results were recorded. Normal predicted
values for FVC were determined,[19,21] and the ratio of actual
measurements and the predicted value (FVCPred%) in each
subject were calculated. The ratio of FEV1 to FVC (FEV1/FVC)
was also calculated. TheMVV, which is understood as maximum
ventilatory capacity[22] reﬂecting both inspiratory and expiratory
phase dysfunction and airway resistance,[18] was tested also using
Pony FX for a 12-second period, and the result was calculated to
obtain a L/min value. At least 2 MVV data points were obtained
with at least 1-minute time interval, and the highest value was
recorded. Predicted value for MVV (MVVPred%) was also
determined based on previous studies[17,23]; and the ratio of
actual measurements and the predicted value of each subject were
calculated. Both MIP and MEP which measure the strength of
each inspiratory and expiratorymuscles[24] were performed using
respiratory pressure manometer (MicroRPM, CareFushion,
Hoechberg, Germany) until 2 maximal values were reproducible,
and the greatest pressure value obtained with variation <10%
among the 3 highest values was chosen. The measured value and
the percentage of the expected normal value (MIPPred% and
MEPPred%) were considered.
[21] Each test maneuver was
performed together by a doctor and a trained physical therapist,
and brief demonstration of each maneuver was conducted before
initiating the test.
The pCO2 was measured overnight in a noninvasive and
continuous manner using a transcutaneous oximetry/capnometry
device (SenTec AG; Therwil, Milwaukee, WI),[25] without a
mechanical ventilator, and the maximal value of measured
transcutaneous CO2 was considered. We considered the pCO2
value because the ventilatory dysfunction in this group is
generally due to alveolar hypoventilation,[11,12] which can be
predicted by isolated nocturnal hypercapnia.[26] Apnea–hypo-
pnea index was also calculated from polysomnography
performed on the same night (SleepTrek3; Grass Technologies,
West Warwick, RI).
We ﬁrst analyzed the pulmonary function parameters (i.e.,
FVC, FVCPred%, FEV1, FEV1Pred%, FEV1/FVC, MVV,
MVVPred%, MIP, MIPPred%, MEP, and MEPPred%) and
demographic data (i.e., age, height, weight, body mass index,
duration from initiation of mechanical ventilation, and number
of CTG repeats), and their correlation with pCO2. Then we
performed subgroup analysis by dividing the subjects into 2
subgroups according to usage of mechanical ventilation. We
compared the mean values of each pulmonary function
parameters among the subgroups.2.3. Statistical analysis
The aim of this study was to determine the correlation between
pCO2 and the pulmonary function parameters. As this was the
ﬁrst study to determine this correlation, we set to get signiﬁcant
result (P< .05) with sufﬁcient power (80%) to detect at least
correlation of 0.4. Therefore, the minimum required sample size
for this study was 46.
Bivariate analysis was performed for each pulmonary function
parameter, includingMVV, FVC, FEV1,MIP,MEP, and ratios of
Suh et al. Medicine (2019) 98:18 www.md-journal.comtheir measure values to predicted values. Trend lines were drawn
for the measured value/predicted values of FVC, FEV1, andMVV
on a scatter plot. The independent t test was used to compare the
mean values of each parameter in the subgroup analysis. Missing
data were not included in the analysis. The software SPSS version
24 (IBM Corp., Armonk, NY) was used. Values of P< .05 were
considered statistically signiﬁcant.3. Results
3.1. Basic demographic information
Among the 87 eligible subjects, pulmonary function evaluation
was performed in 50 subjects (mean age: 42.9±11.1 years) with
DM1. Test was not available in 13 subjects due to intelectual
disabilities, and in 24 subjects due to acute medical conditions.
Diagnostic conﬁrmation was made by electrodiagnostic study
and genetic study, showing abnormal GTC repeat expansion on
DMPK gene. Sex was evenly distributed in the subject group with
DM1, 46.0% of whom were male. Percussion myotonia was
detected in all except 2 subjects, whereas grip myotonia was
noticed in 26 subjects. The anthropometric data of the subjects
are summarized in Table 1. Thirty-six out of the 50 subjects with
DM1 were under mechanical ventilation. Only 14 subjects had
polysomnography data.3.2. Comparing ventilator users versus nonusers with DM1
We divided the subjects into 2 groups according to usage of
mechanical ventilation. Thirty-six subjects were under mechani-
cal ventilation with 35.9months of mean duration since initiationTable 1
Difference in each parameter among ventilator users and nonusers
in subjects with DM1.
Total
(n=50)
Ventilator users
(n=36)
Nonusers
(n=14) P
Age, y 42.9±11.1 42.9±11.1 22.2±5.3 .06
Height, cm 162.8±7.8 162.2±8.2 164.4±6.9 .35
Weight, kg 59.9±15.2 59.4±16.5 61.2±11.7 .66
BMI 22.6±5.6 22.5±6.1 22.7±4.2 .93
CTG repeat
∗
530.1±338.5 540.2±401.3 533.3±134.3 .94
AHI† 32.6±20.8 32.6±20.8 N/A —
pCO2, mm Hg 42.7±7.0 45.0±6.8 37.0±3.2 <.001
‡
FVC, L 2.0±0.9 1.8±1.0 2.4±0.7 .04‡
FVCPred, % 54.2±19.4 50.4±19.5 63.8±16.2 .02
‡
FEV1, L 1.5±0.6 1.4±0.7 1.8±0.4 .02
‡
FEV1Pred, % 54.2±19.4 46.7±18.5 57.6±14.2 .03
‡
FEV1/FVC, % 77.6±16.6 77.6±17.4 77.7±14.8 .99
MVV, L/min 46.5±22.5 42.0±24.0 58.1±12.2 .003x
MVVPred, % 44.0±17.8 39.9±18.1 54.5±12.2 .002
x
MIP, cmH2O 41.2±16.1 40.6±17.7 42.9±11.3 .58
MIPPred, % 50.4±18.6 49.4±19.2 53.0±17.4 .54
MEP, cmH2O 44.5±15.4 43.9±17.5 45.9±8.2 .68
MEPPred, % 40.2±14.6 39.3±15.2 42.6±13.5 .45
Data presented as mean ± standard deviation.
AHI=apnea-hypopnea index, BMI=body mass index, CTG= cytosine–thymine–guanine, DM1=
myotonic muscular dystrophy type1, FEV1= forced expiratory volume in 1 second, FVC= forced vital
capacity, MEP=maximal expiratory pressure, MIP=maximal inspiratory pressure, MVV=maximum
voluntary ventilation, N/A=not applicable, pCO2=partial pressure of carbon dioxide, Pred=predicted.∗
Mean CTG repeat was calculated among 32 out of 36 ventilator user and 9 out of 14 nonusers in
subjects with DM1.
† Polysomnography was performed among 14 subjects only in the ventilator user group.
‡P< .05 and xP< .01 comparing the values among ventilator users and nonusers.
3and 14 subjects were nonusers. The initiation of mechanical
ventilation in this group was decided under previously described
criteria[27–29] and procedures.[29] Although they showed differ-
ence in age, the difference was not statistically signiﬁcant. Mean
pCO2 of ventilator users and nonusers was 45.0 and 37.0 mm
Hg, respectively (P< .001). The parameters FVC, FVCPred%,
FEV1, FEV1Pred%, MVV, and MVVPred% all showed signiﬁcant
differences between the 2 subgroups, but the P values for the
differences in MVV and MVVPred% were lower than those for
other parameters (Table 1).3.3. Correlation between pulmonary function parameters
and trends of decline
Most of the pulmonary function test parameters demonstrated
signiﬁcant correlation with one another in subjects with DM1 in
the bivariate analysis. Table 2 shows bivariate correlation
between hypdercapnia and the pulmonary function parameters.
It shows signiﬁcant correlation of FVC, FVCPred%, FEV1,
FEV1Pred%, MVV, and MVVPred% with hypercapnia. Further-
more, hypercapnia showed signiﬁcant correlation with duration
from initiation of mechanical ventilation for subjects under
mechanical ventilation (r=0.390, P= .02). However, it did not
show signiﬁcant correlation with age (r=0.031, P= .83), height
(r=0.009, P= .95), weight (r=0.099, P= .49), bodymass index
(r=0.115, P= .43), CTG repeats (r=0.021, P= .90), nor
apnea–hypopnea index (r=0.475, P= .09).
Figure 1 shows the trend lines drawn for measured/predicted
value (%) of FVC, FEV1, and MVV on a scatter plot. The trend
lines for DM1 ran parallel. At the same given pCO2, the
measured/predicted value of MVV was the lowest while that of
FVC was the highest.
4. Discussion
This prospective study aimed to analyze several pulmonary
function parameters in subjects with DM1 to reveal clues
explaining early ventilation failure in these individuals, focusing
on differences in the declining patterns of pulmonary function
parameters. We assumed that delayed relaxation of theTable 2
Bivariate correlation between hypercapnia and each pulmonary
function parameter.
DM1 (n=50)
FVC 0.298∗ (.04)
FVCPred 0.362∗∗ (.01)
FEV1 0.301∗ (.03)
FEV1Predv 0.345∗ (.01)
FEV1/FVC 0.003 (.98)
MVV 0.291∗ (.04)
MVVPred 0.353∗ (.01)
MIP 0.140 (.33)
MIPPred 0.185 (.20)
MEP 0.156 (.28)
MEPPred 0.236 (.10)
Data are shown as Pearson coefﬁcient (P value).
∗
P< .05.
∗∗
P< .01.
DM1=myotonic muscular dystrophy type1, FEV1= forced expiratory volume in 1 second, FVC=
forced vital capacity, MEP=maximal expiratory pressure, MIP=maximal inspiratory pressure, MVV=
maximum voluntary ventilation.
Figure 1. Ratio of measured and predicted values of pulmonary function parameters in relation to hypercapnia. Measured/predicted values of FVC (n=50, gray
diagonal), FEV1 (white triangle), and MVV (black square) are depicted on the scatter plot in relation to hypercapnia. Trend lines were drawn for measured/predicted
value of FVC (dash-single dotted line), FEV1 (dashed line), and MVV (solid line) on the same scatter plot. FVC= functional vital capacity, FEV1= forced expiratory
volume in 1 second.
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rhythm and lead to the progression of ventilation failure, even
with adequate vital capacity. We hypothesized that MVV
decreases before other parameters, such as FVC, in subjects
with DM1, and that MVV would decline more abruptly in
correlation with progression of respiratory dysfunction in
subjects with DM1.
In this study, we performed correlation analysis of different
pulmonary function parameters with hypercapnia in subjects
with DM1 FVC, FEV1, and MVV demonstrated a signiﬁcant
negative correlation with hypercapnia, whereas MIP and MEP
did not. Although the declining pattern of MVV was not
signiﬁcantly different compared with FVC or FEV1 as we
hypothesized, MVVPred% decreased ﬁrst among all the param-
eters. Moreover, the P value for the difference in MVVPred%
between ventilator users and nonusers was the lowest. Although
performed in part of the study population, apnea index did not
show signiﬁcant correlation with pCO2.
Chronic hypoventilation in MMD has been explained in
various prior studies. A central cause of hypoventilation is
dominant among the theories posited by these studies. Carroll
et al[30] suggested the possibility of a central factor underlying
respiratory dysfunction in MMD by showing decreasing
respiratory response with increasing CO2 concentration. Al-
though Begin et al opposed this idea by demonstrating that
decreased respiratory response may not be due to a central
factor,[31] and explained the phenomenon on the basis of
inspiratory muscle weakness,[32] Serisier et al[33] insisted that
dysfunction of medullary respiratory control is related to
decreased respiratory response in MMD because this cannot4be explained purely by respiratory muscle weakness. Poussel
et al[14] insisted that alveolar hypoventilation in DM1 is
independent of respiratory weakness, and provide evidences to
support a central cause of CO2 insensitivity. Furthermore, studies
have reported neuronal loss in the medullary respiratory center in
MMD.[34–36] Other evidences also support the association
between respiratory muscle weakness and respiratory dysfunc-
tion. Misuri et al[16] reported that elastic load and respiratory
muscle weakness are responsible for a rapid and shallow
breathing pattern, leading to chronic CO2 retention in patients
with neuromuscular diseases, which is similar to the suggestion of
Begin et al.[31,32]
Nevertheless, apnea index and pulmonary function parameters
representing respiratory muscle power, such and MIP and MEP,
did not show better correlation with hypercapnia than FVC,
FEV1, or MVV in subjects with DM1 in the present study. The
earliest reduction was observed in MVVPred%, and the P values
for the differences in MVV and MVVPred% were the least
between the subjects with DM1 who were under mechanical
ventilation and those who were not. We focused on dysfunction
of elastic recoil or myotonic features of the respiratory muscles in
this patient group to obtain an additional explanation of the
cause of chronic hypoventilation.
Many studies have been conducted on myotonic movements in
the respiratory muscles of patients with MMD. Fluoroscopic
ﬁndings have revealed jerky movements of diaphragm and
delayed relaxation patterns into normal position after contrac-
tion.[37] Electromyographic ﬁndings have revealed the myotonic
movements in the respiratory muscles of these patients.[10,38]
Recently, low maximum relaxation rate compared with healthy
Suh et al. Medicine (2019) 98:18 www.md-journal.comsubjects has also been shown to indicate delayed relaxation of the
respiratory muscles in DM1.[39] However, previous studies have
not investigated the relationship between the abnormal move-
ment pattern of the respiratory muscle and respiratory dysfunc-
tion.
It is known that MVV is dependent on both inspiratory and
expiratory breathing effort; inspiratory air ﬂow is dependent only
on inspiratory muscle power, whereas expiratory air ﬂow relies
mainly on lung recoil.[40] In normal subjects, lung recoil is known
to be the major determinant of expiratory air ﬂow in performing
MVV. The same would apply to patients with DM1, given that
they also perform MVV in the midrange of vital capacity. In this
sense, MVV reﬂects the efﬁciency of lung recoil. The breathing
pattern in MMD was described in a study by Bogaard et al,[41]
who described a wide range of irregularity during the entire
breathing period. Accordingly, pulmonary parameters that are
based on instantaneous values, such as MIP, MEP, and even
FVC, may not accurately reﬂect the variant pattern of respiration
in patients with DM1. Thus, MVV may be more informative in
reﬂecting the respiratory status of these patients.
The limitations of this study include lack of sensitivity/
speciﬁcity evaluation of MVV in relation to actual electromyo-
graphic patterns of the respiratory muscles in subjects with DM1.
The relatively small number of subjects who underwent
polysomnography is another limitation. However, this study
focuses on the declining trend of MVV in DM1 compared with
other pulmonary function parameters, not its exact signiﬁcance.
Furthermore, this study does not aim to oppose the role of central
dysfunction in chronic hypoventilation in this disease group,
rather suggesting additional consideration. Further studies
including sensitivity/speciﬁcity evaluation of MVV and its
comparison with other measures, such as maximum relaxation
rate[39] and larger sample sizes with more apnea index data, will
be necessary to support our results.
This study demonstrates a correlation between MVV, along
with FVC and FEV1, and the progression of respiratory
dysfunction in patients with DM1. Not being a well-studied
pulmonary function parameter, MVV is excluded from routine
pulmonary function tests in most laboratories. However, lower
MVV may be one of the most relevant parameters and one of the
early signs of CO2 retention in patients with DM1. Thus, while
screening ventilation failure in patients with DM1, MVV should
be carefully considered alongside other routine measures.Acknowledgments
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